Ap­pil­i's Covid-19 oral an­tivi­ral fails PhI­II tri­al; On­col­o­gy biotech Ankyra rais­es $45M in Se­ries B

Ap­pili Ther­a­peu­tics’s in­ves­ti­ga­tion­al oral an­tivi­ral Avi­gan/Reeqonus failed in a Phase III tri­al, the biotech said in a state­ment this morn­ing.

The No­va Sco­tia biotech’s PRESECO tri­al, which en­rolled more than 1,200 pa­tients to test a treat­ment for mild-to-mod­er­ate Covid-19, did not achieve sta­tis­ti­cal sig­nif­i­cance on the pri­ma­ry end­point of time to sus­tained clin­i­cal re­cov­ery.

Ad­di­tion­al analy­ses of the tri­al da­ta are on­go­ing, ac­cord­ing to the biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA